Sarepta Therapeutics, Inc. - Common Stock (SRPT)
Sarepta Therapeutics, Inc. - Common Stock (SRPT) last closed at $23.21 (as of 2026-09-02). On Shishin's four-engine momentum model it scored 35/100, flagged by the Suzaku engine on its most recent scan appearance (2026-09-02). It has surfaced in 2 daily scans since 2026-08-28. The figures below are research data, the Shishin Score and the momentum, trend, and volatility indicators the engines observe, not investment advice.
Price updates daily; the engine read reflects SRPT's most recent scan appearance. Shishin's live daily signals are published each morning on the rankings board.
SRPT did not make Shishin's board on 2026-09-02: score 35 is below the 62 board threshold. This is a mechanical screen result, not a view on the company.
SRPT's Shishin Score has faded 30 points (from 65 to 35/100) across its recent scans, momentum-of-score is cooling.
What is SRPT's Shishin momentum score?
As of 2026-09-02, SRPT scores 35/100 on Shishin's four-engine composite, flagged by the Suzaku engine. The score blends momentum, trend, and volatility indicators on a 0 to 100 scale.
Is SRPT showing a momentum setup?
SRPT's current setup state is "OTHER." This describes what the engines observe in the chart structure, it is a data classification, not a recommendation to buy or sell.
Which Shishin engine flags SRPT?
Most recently the Suzaku engine. Each of the four guardians is tuned for a different market regime.
How often has SRPT appeared in Shishin scans?
SRPT has appeared in 2 daily scans since 2026-08-28. Recurring appearances indicate a persistent setup; one-off appearances are more transient.
How is the Shishin Score calculated?
The Shishin Score (0 to 100) is a weighted blend of momentum (multi-horizon returns), trend (moving-average stack, distance from MAs), and volatility/liquidity (ADR, ATR, dollar volume) indicators, scored per the engine active for the current market regime.
Research data, not investment advice. Shishin publishes what its systematic engines observe; it does not recommend buying or selling any security, and is not a registered investment adviser or broker-dealer. See our risk disclosure.